Sanjay D. Khare, PhD
President and CEO, Chairman of the Board
Dr. Khare founded ImmunGene in 2008, where he has been serving as a President and CEO. Previously, Dr. Khare spent almost 9 years at Amgen Inc with increasing responsibility to Scientific Director in the department of Inflammation/Immunology. While at Amgen, Dr. Khare co-discovered key immune co-stimulatory molecules such as B7RP1 and B cell activating Factor (e.g. BAFF). Dr. Khare led several drug discovery programs related to immune cell costimulation and bifunctional molecules to optimize therapeutics. Dr. Khare is co-inventor of several patents while working in Amgen and as an advisor to the start up Biotech companies. Several of these inventions have resulted in more than US$1B potential deals from large Pharmaceutical companies. Dr. Khare coauthored more than 50 scientific papers, abstracts and edited a book on TNF superfamily. Dr. Khare has successfully capitalized ImmunGene from Angel investors, VC fundings, non-profit organization (LLS) and the NIH-SBIR. Sanjay received his Ph.D. in Immunology at the All-India Institute of Medical Sciences, New Delhi, India and did his postdoctoral fellowship in the Immunology department at the Mayo Clinic and Medical School. He is a recipient of ASHI scholar award in 1997.
Michael J. Gresser, PhD
Chief Scientific Officer, ImmunGene Board Member and SAB Member
Dr. Gresser received his Ph.D in Biochemistry in 1976 from Brandeis University. He did postdoctoral studies at the Molecular Biology Institute at UCLA under the supervision of Paul D. Boyer. In 1980 Mike joined the Department of Chemistry at Simon Fraser University in Burnaby, British Columbia, and progressed to Professor of Chemistry. While there Mike received the Excellence in Teaching Award, and did research on the biochemistry of Vanadium V, and on the mitochondrial ATPase. In 1988 Mike Joined the Merck Frosst Center for Therapeutic Research in Kirkland, Quebec as Director of Biochemistry. Over the next twelve years Mike progressed through the ranks of Senior Director, then Executive Director of Biochemistry and Molecular Biology. Mike's team worked on a variety of small molecule drug discovery programs, resulting in the introduction of numerous molecules into clinical trials. Two of these molecules, Singulair and Vioxx, became products. In 2000 Mike joined Amgen Inc. in Thousand Oaks, California, as Vice President of Research for Inflammation, where he remained until April, 2006. For two years Mike served as Head of Neuroscience Research as well as Inflammation Research. Mike's team at Amgen worked on taking many molecular targets, introducing numerous small molecules, human antibodies and other proteins into development. Currently Mike is a Visiting Scholar at the Molecular Biology Institute at UCLA, and works as a consultant with Clarity Therapeutics Consulting.
Raj K. Sachdev, PhD
Chief Operating Officer, ImmunGene Board Member
Dr. Sachdev received his PhD, in Chemical Engineering from Biochemical Engineering Research Center, Indian Institute of Technology, New Delhi in 1979. After post doctoral work at various institutions: Technical University of Denmark, National Institute of Health, Maryland, and Drexel University, Philadelphia, Raj joined Amgen Inc. as a Process Development Research Scientist in Dec. 1984. He gained extensive experience in Microbial Fermentation/Mammalian Cell Culture Process Development, Scale up, Yield Improvement, Optimization, Technology Transfer and Manufacturing Technical Support at Amgen with increasing responsibilities. Raj joined Baxter Bioscience in 1999 as Manager of the Technical Operations Group that provided manufacturing support for Factor-VIII production, including Cell culture, Purification, and Formulation and Lyophilization unit operations. He moved to Shire HGT in Cambridge MA, and joined as Senior Director of Manufacturing Technical Support. Raj has two process patents and is coauthor of several publications/presentations.
Daniel F. Hoth, MD
Chief Medical Officer
Dr. Hoth is a medical oncologist with more than thirty years experience in clinical development of investigational drugs in cancer and infectious disease. From 1980-1987 he served at the National Cancer Institute as chief, investigational drug branch, responsible for all clinical investigations of IND stage anticancer pharmaceuticals. From 1987-1993 he was director, Division of AIDS at the National Institute of Allergy and Infectious Disease. Subsequently he served as senior vice president, development, and chief medical officer of Axys Pharmaceuticals, as well as at Cell Genesys as senior vice president and chief medical officer (1993-1997).
His experience includes several clinical/scientific advisory Boards, as well as the Board of Directors of four companies. He has advised or developed dozens of clinical development programs in oncology. He has participated in five NDAs. He has experience developing small molecules, antibodies, cytokines, gene therapy, and vaccines. He also has served as a consultant to both FDA and NIH in oncology drug development. In addition, he teaches oncology drug development at UCSF.
Linda M. Pullan, PhD
Chief Business Officer
Dr. Pullan has over 20 years of drug industry experience beginning in drug discovery at what is now Pfizer, becoming a project team leader at what is now AstraZeneca (contributing to the development of Seroquel the multi-billion dollar anti-psychotic. Linda then switched to licensing, and subsequently joined Amgen as head of oncology and hematology licensing, leaving to become vice president, business development at Kosan Biosciences and more recently a biotech business development consultant.
John H. Tran, CPA
Chief Financial Officer
John Tran has spent over 19 years in senior financial positions in the life sciences industry ranging from biotech, specialty pharmaceuticals, diagnostic and medical device companies and at a professional service firm. John held various executive roles at public and private biotechs and medical device companies including chief financial officer of Adecit Bio; chief accounting officer at NGM Biopharmaceuticals, Anesiva and Vermillion; vice president, finance and administration at Adamas Pharmaceuticals and Spinal Kinetics and held various leadership roles in Kyphon and Medtronic. Prior to joining the industry, John served as an audit manager in the Audit and Assurance Practice with PricewaterhouseCoopers LLP. John received his Bachelor of Art degrees from the University of California at Santa Barbara in Biology and Business Economics with Accounting Emphasis. John is also a certified public accountant in the State of California.